AIDS Research and Treatment

Global HIV/AIDS Clinical and Translational Pharmacology


Publishing date
15 Apr 2012
Status
Published
Submission deadline
15 Oct 2011

Lead Editor

1NYS Center of Excellence in Bioinformatics and Life Sciences University at Buffalo, Buffalo, NY 14263, USA

2Department of Clinical Pharmacology University of Cape Town, Rondebosch 7701, South Africa

3School of Pharmacy, University of Zimbabwe, Harare, Zimbabwe

4School of Pharmacy and Pharmaceutical Sciences, NYS Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, NY 14263, USA


Global HIV/AIDS Clinical and Translational Pharmacology

Description

The development of diagnostic and therapeutic advances has transformed HIV infection into a chronic disease. While these benefits are available in resource-rich countries (RRCs), global efforts are underway to provide antiretroviral access to the millions of HIV-infected individuals in resource-limited countries (RLCs). Combination antiretroviral therapy (cART) achieves viral suppression in many adherent patients. Appreciation of ongoing low-level viremia during cART, latent reservoirs of integrated viral DNA, and chronic inflammation has led to new efforts to augment suppression, purge latent viral reservoirs, and reduce microbial translocation and end-organ disease. The presence of coinfections with tuberculosis, malaria, and viral hepatitis (HCV and HBV), as well as cancer, creates important pharmacologic challenges including drug interactions, toxicity monitoring, and pharmacogenomic testing.

The requirement for medications for coinfections and noninfectious comorbidities contributes to the challenge of conducting rapid, efficient, and cost-effective clinical pharmacology research. New research areas in preexposure prevention, pediatric cART, and microbicides also include clinical pharmacology. This research agenda may best be facilitated through a global, translational pharmacology research effort among academic, industrial, regulatory, and community partnerships. The need for human and laboratory capacity building with a comprehensive quality assurance program is significant and should be integrated with research planning and implementation. This approach is likely to accelerate the use of new treatments in countries that are most impacted by HIV and other infectious diseases within the global community. Potential topics include, but are not limited to:

  • Recent advances in antiretroviral therapy
  • Fixed-dose combinations for cART
  • Bioequivalence testing of generic ARTs
  • Drug interactions
  • Therapeutic drug monitoring
  • Traditional medicine use with cART
  • Gender, ethnicity, and ARV pharmacokinetics
  • Formulation strategies to maximize ART availability
  • Nanotechnology and translational research for cART
  • Advances in the treatment of HCV and HBV in HIV-infected individuals
  • Advances in the treatment of TB in HIV-infected individuals
  • Advances in the treatment of malaria in HIV-infected individuals
  • Pharmacogenomic applications in cART
  • HIV reservoirs and cARV biodistribution
  • Treatment of cancer in HIV-infected individuals

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/art/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 973627
  • - Editorial

Global HIV/AIDS Clinical and Translational Pharmacology

Gene D. Morse | Gary Maartens | ... | Qing Ma
  • Special Issue
  • - Volume 2012
  • - Article ID 874083
  • - Review Article

TB and HIV Therapeutics: Pharmacology Research Priorities

Kelly E. Dooley | Peter S. Kim | ... | Richard Hafner
  • Special Issue
  • - Volume 2012
  • - Article ID 953743
  • - Research Article

Prevalence and Risk Factors Associated with Precancerous Cervical Cancer Lesions among HIV-Infected Women in Resource-Limited Settings

Peter Memiah | Wangeci Mbuthia | ... | Sibhatu Biadgilign
  • Special Issue
  • - Volume 2012
  • - Article ID 948059
  • - Review Article

Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings

Wirach Maek-a-Nantawat | Anchalee Avihingsanon | Pirapon June Ohata
  • Special Issue
  • - Volume 2012
  • - Article ID 186987
  • - Clinical Study

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

Thomas Kakuda | Vanitha Sekar | ... | Joseph Mrus
  • Special Issue
  • - Volume 2012
  • - Article ID 434171
  • - Research Article

The Impact of Herbal Drug Use on Adverse Drug Reaction Profiles of Patients on Antiretroviral Therapy in Zimbabwe

Tinashe Mudzviti | Charles C. Maponga | ... | Gene D. Morse
  • Special Issue
  • - Volume 2012
  • - Article ID 703604
  • - Research Article

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults

Fatai A. Fehintola | Kimberly K. Scarsi | ... | Francesca T. Aweeka
  • Special Issue
  • - Volume 2012
  • - Article ID 574656
  • - Review Article

Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa

Ayalu A. Reda | Sibhatu Biadgilign
  • Special Issue
  • - Volume 2012
  • - Article ID 105980
  • - Clinical Study

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults

Mohammed Lamorde | Pauline Byakika-Kibwika | ... | Concepta Merry
AIDS Research and Treatment
 Journal metrics
Acceptance rate17%
Submission to final decision90 days
Acceptance to publication33 days
CiteScore3.200
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.